In The Press

In The Press

Seven and Eight Biopharma’s BDB001 in Combination with an anti-PD-L1 mAb Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 SITC Annual Meeting
  • November 13, 2021
  • Julie Ha

EDISON, N.J.–(BUSINESS WIRE)–Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announces the presentation of interim Phase 1 data for BDB001 in combination with atezolizumab in advanced solid tumors at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. BDB001 is […]

Read More
Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 dual agonist BDB001 in anti-PD-1 / anti-PD-L1 Refractory Solid Tumors
  • September 7, 2021
  • Julie Ha

EDISON, N.J. –(BUSINESS WIRE)– Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that the first patient has been treated in a Phase 2 clinical trial evaluating BDB001 in advanced solid tumors at The University of Texas MD […]

Read More
Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 dual agonist BDB018 in Advanced Solid Tumors
  • June 23, 2021
  • Julie Ha

  EDISON, N.J. –(BUSINESS WIRE)– Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that the first patient was treated in a First-in-Human Phase 1 clinical trial evaluating BDB018 in advanced solid tumors at Florida Cancer Specialists & […]

Read More
Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual Meeting
  • June 7, 2021
  • Julie Ha

  EDISON, N.J., –(BUSINESS WIRE)– Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announces the presentation of Phase 1 data for BDB001 in combination with pembrolizumab in advanced solid tumors at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. […]

Read More
Institut Bergonié and Seven and Eight Biopharmaceuticals Inc. Announce the First Patient Treated in the AGADIR Study of BDB001 in Combination with Atezolizumab and Immunogenic Radiotherapy in Solid Tumors
  • May 18, 2021
  • Julie Ha

  The AGADIR study is sponsored by Institut Bergonié, as part of their collaboration with Seven and Eight Biopharmaceuticals Inc., to advance the development of new immunotherapies to treat cancer PARIS, France & EDISON, N.J.–(BUSINESS WIRE)–Institut Bergonié, a cancer center based in Bordeaux, and Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company specializing […]

Read More
Seven and Eight Biopharmaceuticals Inc. Announces Acceptance of BDB001 in Combination with Pembrolizumab Interim Data to be Presented in a Poster Discussion at the 2021 ASCO Annual Meeting
  • April 28, 2021
  • Julie Ha

  EDISON, N.J. –(BUSINESS WIRE)– Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.  The abstract detail […]

Read More
Seven and Eight Biopharma Presents Promising Interim Phase 1 Results for BDB001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
  • November 9, 2020
  • Melissa Harney

EDISON, N.J. – Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced interim Phase 1 results evaluating BDB001, its Toll-like receptor 7/8 (TLR7/8) agonist (NCT03486301), at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting to […]

Read More
TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product
  • December 9, 2019
  • admin

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – December 9, 2019 – Taiwan Liposome Company, Ltd. (“TLC”) (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the signing of […]

Read More
Seven and Eight BioPharmaceuticals, Inc. Announces Clinical Collaboration to Evaluate BDB001 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
  • wpengine

EDISON, N.J.–(BUSINESS WIRE)–Seven and Eight BioPharmaceuticals Inc. announced today that it has signed a clinical research collaboration agreement with Merck (known as MSD outside the US and Canada), through a subsidiary, to explore the combination of Seven and Eight’s BDB001, an immune modulator targeting toll-like receptors (TLR) 7 and 8, and Merck’s anti-PD-1 therapy, KEYTRUDA® […]

Read More
Seven and Eight Biopharmaceuticals Inc. Announces Clinical Collaboration
  • June 19, 2019
  • admin

EDISON, N.J.–(BUSINESS WIRE)–Seven and Eight Biopharmaceuticals Inc. today announced that it has signed a clinical research collaboration agreement with Roche to explore the combination of Seven and Eight’s BDB001, an immune modulator targeting toll-like receptors (TLR) 7 and 8, and atezolizumab, a monoclonal antibody against the checkpoint target of PD-L1, in treating solid tumors. “We […]

Read More